

**Login to  
16-ICML Abstract Submission online system  
>>> myaccount.icml.ch**

**1) Already registered to MyICML?** 

**2) Not yet registered?** 



## MyICML

Enter your email address and password if an ICML account has already been created or if you participated in 15-ICML and accessed to the online resources.

Email

Password

[Reset password](#)

Remember me

 Login

## Not yet registered?

If you don't have an ICML account yet, create one here.

 Create a new account

# 1) Already registered to MyICML?

## MyICML

Enter your email address and password if an ICML account has already been created or if you participated in 15-ICML and accessed to the online resources.

Email

Password

[Reset password](#)

Remember me

[Login](#)



MyICML

[My registration](#)

[My abstract submission](#)

## MyICML

### My Account Details

**Qualification** Mrs.

**First Name** Cristiana

**Middle name**

**Last Name** Brentan

**Gender** Female

**Email** cristiana.brentan@icml.ch

**Work Phone** +41 (0)91 922 0575

**Mobile Phone** +41 (0)76 750 5465

**Work Place** Foundation for the IOR (Institute of Oncology Research)

**Department** ICML Secretariat

**Country** CH

**Address** via Vincenzo Vela 6

**Address 2<sup>nd</sup> line**

**Postal code** 6500

**City** Bellinzona

[Edit MyICML](#)

[Edit invoicing details](#)



## 2) Not yet registered?

### Not yet registered?

If you don't have an ICML account yet, create one here.

+ Create a new account



Please provide your email address to verify if it's already registered.

### MyICML account: check email

Enter your email address here to check if it has been saved on our system

Email

Save and continue →



**A.** If your email is already registered on our platform, you can go back to the login page and reset your password.

Your email address has already been saved in our system.

 Go to login/reset password

**B.** If your email is not registered on our system yet, you can create your MyICML account, inserting your personal information and setting a password.

## Create your MyICML Account:

Qualification\*

First Name\*  Middle name

Last Name\*

Gender\*  Female  Male  Other

Email\*

Work Phone

Mobile Phone

Work Place\*

Name of Institution, Hospital, Company etc. or Private practice

Department

Country\*

Address\*

Address 2<sup>nd</sup>

Postal code\*  City\*

### Set your password

Password\*  Repeat Password\*

### Privacy Policy\*

I have read and agree to the [Personal Data Protection Policy](#)

As required personal data are handled according to the values of righteousness, correctness and transparency. Terms of our Privacy Policy are available [HERE](#)

Save and create a MyICML account →



## MyICML Account:

Entering your MyICML account, you can view your account details, register to the 16-ICML and submit one or more abstracts.



MyICML

My registration

My abstract submission

MyICML

### My Account Details

#### Qualification

First Name Angela

Middle name

Last Name Kurtz

Gender Female

Email angela.kurtz@icml.ch

## Presenter or submitter

You can submit abstract(s) on your behalf, in your role of **PRESENTER**, or on behalf of the presenter, as **SUBMITTER** (third party submission).



If you are the **presenter**, the system will ask you to confirm or to modify the details you entered to create your MyICML account and to accept the Presenter responsibilities\*

If you are the **submitter**, the system will ask you to provide the Presenter's details and to declare that:

- (s)he is aware you are submitting the abstract on her/his behalf;
- text and any information contained in the abstract, as well as the listing of the authors and information about them (affiliations and conflict of interest disclosures) are provided according to their indications.

As submitter, you will be the first contact for correspondence related to the abstract submission and responsible for forwarding it to the authors in due time.

**\* Presenter responsibilities:**

- The presenter serves as primary contact for all correspondence regarding the abstract (except if there is a Submitter).
- The submission of an abstract constitutes a formal commitment by the person to present the abstract (if accepted) orally or as a poster.
- The presenter of a clinical abstract cannot be an employee of a pharmaceutical and/or diagnostic company. Conversely, employees of such companies may submit and present non-clinical abstracts.

Upon submission of an abstract, the presenter is responsible for the following:



- ensuring that all authors have read the abstract, agreed to be co-authors and accepted the 16-ICML submission policies and regulations;
- forwarding all correspondence regarding the abstract to all co-authors;
- releasing of the permission to the recording of his/her presentation for multimedia coverage, live streaming during the 16-ICML days and inclusion in the 16-ICML webcast service;
- disclosing any conflict of interest related to the data presented in the abstract, declaring the name of the company (s)he or any of the co-authors maintain a "relevant financial relationship" with. Unless otherwise indicated, it is implied that there are no conflicts of interests pertinent to the abstract.  
The relationships that must be declared are: employment or leadership position in a company, consultant or advisory role, stock ownership, honoraria, research funding, travel grants, other remuneration;
- certifying that the same abstract has neither been nor will be previously published before the 16-ICML except for Encore abstracts (abstracts presented at regional or national meetings with  $\leq 1'000$  attendees, EMBT, AACR, ASCO and EHA 2021).

Furthermore, the presenter certifies that the abstract will not be included as such in the scientific material produced in connection with any Satellite symposium held during the 16-ICML;

- declaring how the research was funded and naming the organization(s) funding the study (pharmaceutical, biotech, other commercial company, foundation or academic group).

# Steps to successfully submit your abstract:

The following steps are not to be completed in a specific order, but they are all mandatory:



## Abstract Title

It must not exceed **150 characters** (spaces not included).

Names of cooperative study groups should appear in the title, as they cannot be included in the authors' list.

### Abstract title

Max characters: 150  
Current characters: 211



← → Paragraph Ω [Clipboard] [Link] *I* **B** *I* U  $x_2$   $x^2$  ...

Harry Potter and the Prisoner of Azkaban is a fantasy novel written by British author J. K. Rowling and is the third in the Harry Potter series. The book follows Harry Potter, a young wizard, in his third year at Hogwarts School of Witchcraft and Wizardry.

P 46 WORDS

If the title is longer than the number of characters allowed (the system tolerates a small extra number of characters), you will not be able to save it.



### Abstract title

Max characters: 150  
Current characters: 143



← → Paragraph Ω [Clipboard] [Link] *I* **B** *I* U  $x_2$   $x^2$  ...

Harry Potter and the Prisoner of Azkaban is a fantasy novel written by J. K. Rowling. The book follows Harry in his third year at Hogwarts School of Witchcraft and Wizardry.

P 31 WORDS

[Save and Preview]



(1)

### EA - Encore Abstract

the pertinent sentence will be added to the text: "EA – previously submitted to regional or national meetings with ≤ 1'000 attendees / EBMT / AACR / ASCO / EHA 2021")

- EBMT 2021
- AACR 2021
- ASCO 2021
- EHA 2021
- Regional or national meeting ( ≤ 1'000 attendees)

Encore Abstract +

### Research funding disclosure

- "The research was funded by: ..."

(2)

### Updated analysis

- Previous publication and novel information since it (Note not published but transmitted to reviewers):

max 350 characters

### Ongoing Trial

- The abstract will include only the INTRODUCTION and METHODS sections.

Ongoing Trials abstracts +

### Education Grant

- If my abstract is accepted for oral or poster presentation, I am eligible for a young investigator education grant (I am 35 years old or younger).

Education grants and merit award +

## Abstract options selection:

(3)

### Withdrawal option

- If the abstract is selected for publication only (inclusion in the 16-ICML Abstract Book but NO oral and NO poster presentation) I wish to withdraw it. **No abstract withdrawal request will be accepted if received after the deadline.**

### Placeholder of a Late-breaking abstract

- No Late-breaking abstract will be considered without the submission of the placeholder abstract and the covering letter.

Late-breaking abstracts +

### Preference

Preference of presentation  No preference  Oral presentation  Poster presentation

The Organizing Committee reserves the right to conclusively decide the presentation format, based on the evaluation results and the Scientific Program structure.

Save and Preview

## Adding a co-author (affiliations)

There is no limit to the number of listed co-authors.

Authors will be listed with first and middle name initials, surname, institution, department, city and country.

### Abstract authors

  Kurtz Presenter

 Add coauthor



### Coauthor information

Qualification

First Name\*  Middle Name

Last Name\*

Gender  Female  Male  Other

Email\*

Work Phone

Mobile Phone


Work Place\*  Add a workplace

### Responsibilities\*

- As coauthor, (s)he read the abstract, agreed to be coauthor and accepted submission policies and regulations.

## Co-authors (disclosures)

Conflict of interests pertinent to the abstracts must be declared for each author (presenter and co-authors).



The interface shows two user selection cards. The top card is for Kurtz, with a red 'Presenter' button. The bottom card is for Brentan, with a red 'Conflicts' button. A blue arrow points from the 'Conflicts' button to the right.

- No conflicts of interests pertinent to the abstract to be declared
- Disclosure of any conflict of interest related to the data presented in the abstract is mandatory. Authors must declare the name of the company they maintain a "relevant financial relationship" with. "Relevant financial relationships" are intended those relationships from which they or any individual with whom they directly share their income have received or may receive financial benefit within the past 24 months. The relationships that must be declared are: employment or leadership position in a company – consultant or advisory role – stock ownership – honoraria – research funding – travel grants – other remuneration. Unless otherwise indicated, it is implied that there are no conflicts of interests pertinent to the abstract.



Employment or leadership position

Consultant or advisory role

Stock ownership

Honoraria

Research funding

Travel grants

Other remuneration


 Save and Preview

## Modifying the co-authors' list:

### Abstract authors

↕	 Pizzi Polli	Conflicts
↕	 Brentan	Presenter
↕	 Dalla Riva	Conflicts
↕	 Masolo	Conflicts
 Add coauthor		

If you need to modify the already entered details, click on the pen:



*The presenter's name will be underlined.*

If you need to change authors' order, move the tag accordingly:

### Abstract authors

↕	 Brentan	Presenter
↕	 Pizzi Polli	Conflicts
↕	 Dalla Riva	Conflicts
↕	 Masolo	Conflicts
 Add coauthor		



# Abstract Text

## Abstract text

Max characters: 2500

Current characters: 0

Edit Insert View Format Table

← → Paragraph Ω 📎 📎 *I* **B** *I* U ×<sub>2</sub> ×<sup>2</sup> ...

P 0 WORDS

Only **one** JPEG, GIF or PNG file can be uploaded, with the following resolution criteria:

- Graphs and tables: 800 dpi preferred; 600 dpi minimum;

- Images: 300 dpi minimum. - The system accepts only one file, up to 50 MB.

📄 Save and Preview

Abstract text must not be longer than **2'500 characters** (spaces not included).

All abstracts (except for ongoing trials abstracts) should include the following **four sections**:

- Introduction
- Methods
- Results
- Conclusions

**Compounds** should be mentioned with the generic name in lower case. Commercial names **must** not be used.


**Abbreviations** are permitted but terms must be spelt out at their first mention and followed by the abbreviation in parentheses, i.e. International Conference on Malignant Lymphoma (ICML).

Once the abstract has been submitted, **corrigenda** (corrections, rewording or amendments in the text and change of order in the authors' string) **will not be possible**.

# Inserting an image

## Abstract text

Max characters: 2500  
Current characters: 0

A dialog box titled 'Insert/Edit Image' with a close button (X) in the top right. It has a 'General' tab selected. Under the 'Upload' section, there is an empty text field for the source, an empty text field for the alternative description, an empty text field for the image title, and a dropdown menu for the class set to '100% width'. At the bottom are 'Cancel' and 'Save' buttons.A dialog box titled 'Insert/Edit Image' with a close button (X) in the top right. It has a 'General' tab selected. Under the 'Upload' section, the source field contains the URL 'blob:https://icml-fe.cryms.info/6950e97e-7...', the alternative description field is empty, the image title field contains 'LINFOMI\_LOGO.gif', and the class dropdown is set to '100% width'. At the bottom are 'Cancel' and 'Save' buttons.

**One image can be submitted.**


Only JPEG, GIF or PNG files can be uploaded, with the following resolution criteria:

- Graphs and tables: 800 dpi preferred; 600 dpi minimum;
- Images: 300 dpi minimum.
- The system accepts only one file, up to 50 MB.

Images and tables not adhering to these requirements and images without readable text will be removed from the Abstract Book without further recourse to the first author.

## Abstract text

Max characters: 2500  
Current characters: 0



## Abstract category

+ Basic and Translational Science

+ Cancer Health Disparities

+ Diagnostic and Prognostic Biomarkers

+ Experimental Therapeutics

+ Imaging and Early Detection

+ Late Effects in Lymphoma Survivors

+ Lymphoid Cancers

+ Pathology and Classification of Lymphomas

+ Prevention and Cancer Interception

+ Therapeutics and Clinical Trials in Lymphoma

+ Ongoing Trials

+ Other

### - Basic and Translational Science

- Bioinformatics: Computational and Systems Biology
- Genomics, Epigenomics, and Other -Omics
- Metabolism
- Patient-Derived Xenograft (PDX) Models
- Risk Models
- Tumor Biology and Heterogeneity
- Other


## Selection of Categories

**Some categories have sub-categories (click on the “+” button on the left side of the name to see them).**

**You can select at least one and no more than 3 categories.**

 Save and Preview

## Preview and SUBMISSION:



Nov 30, 2020 - ID: AS28

Test - Handbook

Submission by Presenter

Status: **PENDING**




A green oval highlights the red 'Manage' button, and a green arrow points to it from the right.

Before submitting the abstract, you can modify it (button "Manage" in My Abstract Submission list).

When you have reviewed all the entered information, you can proceed with the submission of your abstract. **You will not be able to make any modifications to submitted abstracts.**








Nov 30, 2020 - ID: AS28

Test - Handbook

Submission by Presenter

Status: **SUBMITTED**



A green oval highlights the red 'View' button, and a green arrow points to it from above.

An email will be sent to the provided address.

Only abstracts submitted within the deadline (**Monday, March 15, 2021, 17:59 CET**) will be considered and evaluated by 16-ICML reviewers.